← Eichor
Condition: Malignant Peripheral Nerve Sheath Tumor Mpnst Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Malignant Peripheral Nerve Sheath Tumor Mpnst

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06041516
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Phase N/A · 13 location(s) · Washington University School of Medicine · NCT03141021
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2 · 1 location(s) · Fudan University · NCT06849986
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT04222413
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Maligna
EARLY_Phase 1 · 1 location(s) · University of Minnesota · NCT06693284
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04872543
SPEARHEAD-3 Pediatric Study
Phase 1/Phase 2 · 10 location(s) · USWM CT, LLC · NCT05642455
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Phase 1/Phase 2 · 2 location(s) · AeRang Kim · NCT06735820
A Study of DEG6498 in Participants With Solid Tumors
Phase 1 · 3 location(s) · Degron Therapeutics Co. · NCT07244835
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06222203
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Phase 2 · 16 location(s) · Memorial Sloan Kettering Cancer Center · NCT05985161
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT04897321
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Phase 2 · 1 location(s) · HRYZ Biotech Co. · NCT06277154
Neurofibromatosis Type 1 Tumor Early Detection Study
Phase N/A · 1 location(s) · David Miller · NCT06515860
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.